Setback For Roche In Valcyte Patent Case As Indian Court Orders A Re-examination
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a major setback to Swiss drug maker Roche, the Madras High Court has directed India's Controller General of Patents to re-examine the patent rights granted to anti-HIV drug Valcyte (valgancyclovir)
You may also be interested in...
Roche Granted Injunction Against Cipla for Trademark Infringement of Valcyte
MUMBAI - Swss drug maker Roche has been granted an injunction by the Bombay High Court against Cipla for trademark infringement of Roche's Valcyte (valgancyclovir), used in the treatment of HIV-related infections
Roche Granted Injunction Against Cipla for Trademark Infringement of Valcyte
MUMBAI - Swss drug maker Roche has been granted an injunction by the Bombay High Court against Cipla for trademark infringement of Roche's Valcyte (valgancyclovir), used in the treatment of HIV-related infections
Cipla Of India To Confront Roche With Valcyte Copy
India's Cipla plans to ramp up a confrontation with F. Hoffman-LaRoche by launching a generic version of the Swiss drug maker's Valcyte (valganciclovir) for treating HIV/AIDS infections. The two companies already are locked in a patent-infringement battle over the Roche drug Tarceva (erlotinib) for treating cancer. A source said Cipla may increase the contention between the two firms by seeking to call its Valcyte copy Valcept, a name so similar to the original it could set off a fight over what is considered in the industry "passing off," a trademark infringement. (Click here for more